These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 21894174)

  • 41. Delay of radical prostatectomy and risk of biochemical progression in men with low risk prostate cancer.
    Freedland SJ; Kane CJ; Amling CL; Aronson WJ; Presti JC; Terris MK;
    J Urol; 2006 Apr; 175(4):1298-302; discussion 1302-3. PubMed ID: 16515984
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Patients aged more than 70 had higher risk of locally advanced prostate cancers and biochemical recurrence in Korea.
    Kim JK; Cho SY; Jeong CW; Lee SB; Ku JH; Hong SK; Byun SS; Kwak C; Him HH; Lee SE; Jeong H
    BJU Int; 2012 Aug; 110(4):505-9. PubMed ID: 22314007
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Site of positive surgical margins influences biochemical recurrence after radical prostatectomy.
    Godoy G; Tareen BU; Lepor H
    BJU Int; 2009 Dec; 104(11):1610-4. PubMed ID: 19549257
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Positive surgical margins after minimally invasive radical prostatectomy in patients with pT2 and pT3a disease could be considered pathological upstaging.
    Ouzzane A; Rozet F; Salas RS; Galiano M; Barret E; Prapotnich D; Cathelineau X
    BJU Int; 2014 Apr; 113(4):586-91. PubMed ID: 23889763
    [TBL] [Abstract][Full Text] [Related]  

  • 45. High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy.
    Savdie R; Horvath LG; Benito RP; Rasiah KK; Haynes AM; Chatfield M; Stricker PD; Turner JJ; Delprado W; Henshall SM; Sutherland RL; Kench JG
    BJU Int; 2012 Jun; 109(12):1794-800. PubMed ID: 21992536
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Does a tertiary Gleason pattern 4 or 5 influence the risk of biochemical relapse after radical prostatectomy for clinically localized prostate cancer?
    Servoll E; Saeter T; Vlatkovic L; Nesland J; Waaler G; Beisland HO
    Scand J Urol Nephrol; 2010 Sep; 44(4):217-22. PubMed ID: 20367396
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of positive surgical margins after radical prostatectomy among pT2 and pT3a prostate cancer.
    Oh JJ; Hong SK; Byun SS; Choe G; Lee SE
    Urol Oncol; 2013 Jul; 31(5):595-600. PubMed ID: 21658977
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biochemical outcome after radical prostatectomy among men with normal preoperative serum prostate-specific antigen levels.
    Freedland SJ; Aronson WJ; Kane CJ; Terris MK; Presti JC; Trock B; Amling CL
    Cancer; 2004 Aug; 101(4):748-53. PubMed ID: 15305405
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group.
    Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2009 Dec; 104(11):1604-9. PubMed ID: 19549124
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphodiesterase Type 5 Inhibitor Use Following Radical Prostatectomy is not Associated with an Increased Risk of Biochemical Recurrence.
    Jo JK; Kim K; Lee SE; Lee JK; Byun SS; Hong SK
    Ann Surg Oncol; 2016 May; 23(5):1760-7. PubMed ID: 26717939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metformin does not affect risk of biochemical recurrence following radical prostatectomy: results from the SEARCH database.
    Allott EH; Abern MR; Gerber L; Keto CJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moorman PG; Freedland SJ
    Prostate Cancer Prostatic Dis; 2013 Dec; 16(4):391-7. PubMed ID: 24100644
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Kim HS; Moreira DM; Smith MR; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2011 Mar; 107(6):924-8. PubMed ID: 20860651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions.
    Saha A; Hamilton-Reeves J; DiGiovanni J
    Cancer Metastasis Rev; 2022 Sep; 41(3):649-671. PubMed ID: 35927363
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Obesity and biochemical recurrence in clinically localised prostate cancer: a systematic review and meta-analysis of 86,490 patients.
    Rivera-Izquierdo M; Pérez de Rojas J; Martínez-Ruiz V; Arrabal-Polo MÁ; Pérez-Gómez B; Jiménez-Moleón JJ
    Prostate Cancer Prostatic Dis; 2022 Sep; 25(3):411-421. PubMed ID: 34987170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Feasibility of a Weight Management Program Tailored for Overweight Men with Localized Prostate Cancer - A Pilot Study.
    Hamilton-Reeves JM; Johnson CN; Hand LK; Bechtel MD; Robertson HL; Michel C; Metcalf M; Chalise P; Mahan NJ; Mirza M; Lee EK; Sullivan DK; Klemp JR; Befort CA; Parker WP; Gibbs HD; Demark-Wahnefried W; Thrasher JB
    Nutr Cancer; 2021; 73(11-12):2671-2686. PubMed ID: 33295204
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mounting Weight of Evidence on the Importance of Body Weight for Men With Prostate Cancer.
    Marshall CH; Joshu CE
    J Clin Oncol; 2020 Jun; 38(18):2007-2009. PubMed ID: 32369400
    [No Abstract]   [Full Text] [Related]  

  • 59. The association of weight change in young adulthood and smoking status with risk of prostate cancer recurrence.
    Khan S; Hicks V; Colditz GA; Kibel AS; Drake BF
    Int J Cancer; 2018 May; 142(10):2011-2018. PubMed ID: 29270988
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer.
    Dickerman BA; Ahearn TU; Giovannucci E; Stampfer MJ; Nguyen PL; Mucci LA; Wilson KM
    Int J Cancer; 2017 Sep; 141(5):933-944. PubMed ID: 28543830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.